Suppr超能文献

目前心脏病的状况:他汀类药物、胆固醇、脂肪和糖。

The current state of heart disease: statins, cholesterol, fat and sugar.

机构信息

Department of Nursing, School of Health Professions and Nursing, Long Island University @ Post, Brookville, New York, USA.

出版信息

Int J Evid Based Healthc. 2019 Sep;17(3):179-186. doi: 10.1097/XEB.0000000000000197.

Abstract

UNLABELLED

After decades of improvement in the outlook for cardiovascular disease (CVD), we are now seeing a plateau. Statins, once believed to be the most important advance in the fight against heart disease, have not mitigated the incidence or prevalence of CVD.

AIM

New research into lipid-lowering drugs is not only questioning their usefulness in primary care, but identifying them as harmful, resulting in the development of other diseases. When the original research is critically analyzed, the data do not reveal drugs that significantly reduce the incidence or prevalence for primary prevention of CVD in the United States.

METHODS

The current article sheds light on our current beliefs into lipid-lowering to treat potential CVD. Through a discussion of the difference between relative risk reduction and absolute risk reduction, the author suggests lifestyle modifications have been and always will be the best way to fight against this deadly chronic disease.

RESULTS

There is over 60 years-worth of scientific research that has been desperately trying to identify sugar as the culprit and driver of CVD disease; however, the medical system continues to fight against fat and cholesterol. This article makes the reader question what the US government, in association with the Medical Establishment (American Heart Association, American Diabetes Association and the American College of Cardiology) have been eschewing for the last 60-70 years as it has NOT been working.

CONCLUSION

The time for a culture-wide paradigm change has come. The author suggests this will only happen if Big Pharma and Big Food industries will change their marketing habits from 'purely taste' to 'best for your health'.

摘要

未加标签

经过几十年改善心血管疾病 (CVD) 的前景,我们现在看到一个平台期。他汀类药物,曾经被认为是对抗心脏病最重要的进展,并没有减轻 CVD 的发病率或患病率。

目的

对降脂药物的新研究不仅质疑它们在初级保健中的有用性,而且还确定它们有害,导致其他疾病的发展。当对原始研究进行批判性分析时,数据并未显示出药物能显著降低美国 CVD 一级预防的发病率或患病率。

方法

目前的文章揭示了我们目前对降脂治疗潜在 CVD 的信念。通过讨论相对风险降低和绝对风险降低之间的差异,作者认为生活方式的改变一直是对抗这种致命慢性病的最佳方法。

结果

有超过 60 年的科学研究一直试图将糖确定为 CVD 疾病的罪魁祸首和驱动因素;然而,医疗系统继续对抗脂肪和胆固醇。本文使读者质疑美国政府与医疗保健机构(美国心脏协会、美国糖尿病协会和美国心脏病学会)在过去 60-70 年中一直回避的问题,因为它没有起作用。

结论

文化范围范式转变的时机已经到来。作者认为,只有大型制药和大型食品行业改变他们的营销习惯,从“纯粹的口味”转变为“对你的健康最好”,这种情况才会发生。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验